Join Us

We invite you to join an exclusive fireside chat with Mitch Gold, CEO of Alpine Immune Sciences. Earlier this year, Alpine was acquired for $4.9 billion by Vertex Pharmaceuticals—the highest value ever paid for a biotech company at its stage of the clinical-regulatory process.

Fenwick partners Effie Toshav and Doug Cogen will join Mitch as he shares insights on Alpine’s journey, what it takes to successfully lead a biotech in the current environment, the M&A process, and emerging trends in the life sciences industry. This is a unique opportunity to hear firsthand about the strategies that fueled Alpine’s success and the evolving landscape of biotech innovation and acquisitions.


About Fenwick’s Pathways to Success Series
Join us for an essential three-part webinar series designed specifically for leaders of late-stage biotech companies. This series will provide in-depth guidance on critical lifecycle moments, featuring insights from industry experts on billion-dollar acquisitions, strategic IPO planning, and emerging M&A trends set to shape 2025. Don’t miss this opportunity to prepare your company for pivotal transitions.

If you have any questions, please contact Marissa Tsang or +1 650-335-6186.

Speakers

Agenda